

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for the process and feasibility evaluations of a new model of primary care service delivery for managing pain and function in patients with knee osteoarthritis (PARTNER)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034526
Article Type:	Protocol
Date Submitted by the Author:	24-Sep-2019
Complete List of Authors:	Bowden, Jocelyn; The University of Sydney, Institute of Bone and Joint Research; Royal North Shore Hospital, Department of Rheumatology Egerton, T; University of Melbourne, Hinman, Rana S.; University of Melbourne, Bennell, Kim; University of Melbourne, CHESM Briggs, Andrew; Curtin University, School of Physiotherapy and Exercise Science Bunker, Stephen; Medibank Kasza, Jessica; Monash University, School of Public Health and Preventive Medicine French, Simon; Macquarie University, Department of Chiropractic Pirotta, Marie; University of Melbourne, General Practice and Primary Care Academic Centre; University of Melbourne, Schofield, Deborah; Macquarie University, Centre for Economic Impacts of Genomic Medicine Zwar, Nicholas; University of New South Wales, School of Public Health and Community Medicine; Bond University, Health Sciences and Medicine Hunter, David; The University of Sydney, Institute of Bone and Joint Research ; Royal North Shore Hospital, Department of Rheumatology
Keywords:	PRIMARY CARE, model of service delivery, Process Evaluation, Clinical Trial, QUALITATIVE RESEARCH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title: Protocol for the process and feasibility evaluations of a new model of primary care service delivery for managing pain and function in patients with knee osteoarthritis (PARTNER)**

**Authors:**

Jocelyn L Bowden, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, NSW, Australia. [jocelyn.bowden@sydney.edu.au](mailto:jocelyn.bowden@sydney.edu.au).

Thorlene Egerton, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia. [thorlene.egerton@unimelb.edu.au](mailto:thorlene.egerton@unimelb.edu.au).

Rana S Hinman, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia. [ranash@unimelb.edu.au](mailto:ranash@unimelb.edu.au).

Kim L Bennell, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia. [k.bennell@unimelb.edu.au](mailto:k.bennell@unimelb.edu.au).

Andrew M Briggs, School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia. [a.briggs@curtin.edu.au](mailto:a.briggs@curtin.edu.au).

Stephen J Bunker, Medibank, Docklands, Victoria, Australia; Honorary Senior Fellow, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia  
[stephen.bunker@medibank.com.au](mailto:stephen.bunker@medibank.com.au).

Jessica Kasza, Biostatistics Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. [jessica.kasza@monash.edu](mailto:jessica.kasza@monash.edu).

Simon D French, Department of Chiropractic, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia. [simon.french@mq.edu.au](mailto:simon.french@mq.edu.au)

Marie Pirotta, Department of General Practice, The University of Melbourne, Melbourne, Victoria, Australia. [m.pirotta@unimelb.edu.au](mailto:m.pirotta@unimelb.edu.au).

Deborah J Schofield, Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW, 2109, Australia. [deborah.schofield@mq.edu.au](mailto:deborah.schofield@mq.edu.au).

Nicholas A Zwar, School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia; Health Sciences and Medicine, Bond University, Gold Coast, Qld, Australia. [n.zwar@unsw.edu.au](mailto:n.zwar@unsw.edu.au).

David J Hunter, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney; Department of Rheumatology, Royal North Shore Hospital, Sydney, NSW, Australia. [david.hunter@sydney.edu.au](mailto:david.hunter@sydney.edu.au).

1  
2  
3  
4  
5  
6  
7 **Correspondence to:**

8 Dr Jocelyn Bowden, Institute of Bone and Joint Research, Kolling Institute, The University of Sydney,  
9 Sydney, NSW, Australia. [jocelyn.bowden@sydney.edu.au](mailto:jocelyn.bowden@sydney.edu.au), Ph: +61 2 9463 1898

10  
11  
12 **Key words:** primary care, model of service delivery, process evaluation, clinical trial, qualitative evaluations  
13

14  
15 **Word Count:** 3853 / 4000  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Abstract

**Introduction:** This protocol outlines the rationale, design and methods for the process and feasibility evaluations of the PARTNER study. PARTNER is a randomised controlled trial to evaluate a new model of service delivery (the PARTNER model) against 'usual care'. PARTNER is designed to encourage greater uptake of key evidence-based non-surgical treatments for knee osteoarthritis (OA) in primary care. The intervention supports general practitioners (GPs) to gain an understanding of the best management options available through online professional development. Their patients receive telephone advice and support for OA management by a centralised, multidisciplinary 'Care Support Team'. We will conduct concurrent process and feasibility evaluations to understand the implementation of this new complex health intervention, identify issues for consideration when interpreting the effectiveness outcomes, and develop recommendations for future implementation, cost effectiveness and scalability.

**Methods and analysis:** The UK Medical Research Council Framework for undertaking a process evaluation of complex interventions and the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) frameworks inform the design of these evaluations. We utilise a mixed methods approach including analysis of survey data, administrative records, consultation records, and semi-structured interviews with general practitioners and their enrolled patients. The analysis will examine fidelity and dose of the intervention, observations of trial setup and implementation, and the quality of the care provided. We will also examine details of "usual care". The semi-structured interviews will be analysed using thematic and content analysis to draw out themes around implementation and acceptability of the model.

**Ethics and dissemination:** The primary study protocol (2016/959) and sub-study protocol (2019/503) have been approved by the Human Research Ethics Committee of the University of Sydney. This evaluation is crucial to explaining the PARTNER study results, and will be used to determine the feasibility of rolling out the intervention in an Australian healthcare context. ACTRN12617001595303, 1/12/2017.

## ARTICLE SUMMARY

### Strengths and limitations of this study

- A comprehensive, pre-planned, process and feasibility evaluation of a complex model of service delivery
- Mixed methods approach, underpinned by theoretical frameworks for design and evaluation of complex health interventions and chronic disease management
- Co-designed by a broad range of stakeholders including general practitioners, people with OA, physiotherapists, rheumatologists, industry groups and policy makers.
- Outcomes from this study will directly contribute to the implementation priorities of the Australian “National Osteoarthritis Strategy”.

## INTRODUCTION

Osteoarthritis (OA) is a leading cause of lower limb pain and disability, affecting more than 2 million Australians.<sup>1</sup> Although there is no cure, there are effective non-surgical treatments for the long-term management of symptomatic OA.<sup>2</sup> In particular, education and advice on OA, exercise and physical activity, and weight management are the core interventions recommended by current clinical guidelines.<sup>3-5</sup> These treatments are, however, often underutilised in primary care, and day-to-day management of Australians with knee OA is inconsistent with these recommendations.<sup>6</sup> We designed the *Effectiveness of a new model of primary care management on knee pain and function in patients with knee osteoarthritis study* (PARTNER), to address this issue.<sup>7</sup> The aim of the PARTNER study is to test a new model of service delivery (the PARTNER model), designed to encourage greater uptake of these key non-surgical treatments in primary care pathways, in comparison to usual care.

The PARTNER model is a complex health intervention (Fig. 1) employing multiple interacting components that target different organisational levels of healthcare delivery.<sup>8</sup> The intervention will target both general practitioners (GPs) and their patients with OA. General practitioners will be provided with online professional development opportunities to gain an understanding of the effective conservative, non-surgical management options available for treatment of patients with OA and endorsed by the Royal Australian College of General Practitioners (RACGP). Their patients will receive tailored advice and support on issues related to the management of OA including physical activity and exercise, weight loss, pain management and other effective self-management behaviours. This support will be delivered remotely for 12-months by a centralised, multidisciplinary 'Care Support Team' (CST) of health professionals trained in best-practice management of OA and health behaviour change.

The effectiveness and cost-effectiveness of this new model is being tested through a two-arm, cluster randomised controlled trial (RCT), and the process and feasibility evaluations described here will be conducted concurrently with the RCT. These evaluations will help us to understand the factors influencing the implementation of the intervention, identify issues for consideration when interpreting the effectiveness results, and enable us to develop recommendations for future implementation of the new model into Australian general practice. This process evaluation and feasibility protocol has two aims, namely:

1. To explain the PARTNER study results in terms of fidelity and engagement with the intervention, and determine:
  - 1.1. whether the intervention and control arms were delivered as intended for both the GPs and patients enrolled in the study,
  - 1.2. what "usual care" entailed, including types and rate of uptake of other services recommended for the patient,
  - 1.3. the types of issues typically identified or actioned during the consultations between the participants and the healthcare professionals in the study (i.e the GPs and CST), and determine the nature of the support and advice provided for each issue,



- 1.4. participants' (GPs and patients) and the CST personnel's perspectives on how, why and for whom the intervention did or did not work, and
  - 1.5. if the primary and secondary outcome effects were due to the nature of the implementation, or to the intervention.<sup>9</sup>
2. To determine the feasibility of having the model adopted broadly in an Australian healthcare context (if the study is found to be effective), specifically:
    - 2.1. are there potential barriers and enablers to rolling the model out in the Australian primary care setting that have not been identified previously? We will look at barriers and enablers at the patient level; professional, organisational and service level (meso); and health systems level (macro)<sup>10</sup>
    - 2.2. do people with OA, and GPs, value the intervention as it was delivered?
    - 2.3. are the results generalisable to other people with OA, healthcare service providers and to different Australian health care contexts (e.g. public or private hospitals).
    - 2.4. Is the intervention cost effective compared to usual care?

## METHODS AND ANALYSIS

### The PARTNER Cluster Randomised Controlled Trial:

The PARTNER study is an investigator-initiated pragmatic RCT. A detailed explanation of the background, theoretical development and protocol for the broader PARTNER study (2016/959) has been described previously<sup>7 11</sup>, and the trial prospectively registered with the Australia New Zealand Clinical Trials Registry (ACTRN12617001595303). The process and feasibility evaluations will be reported in accordance with the Standards for Reporting Implementation Studies (STaRI), and the Consolidated Criteria for Reporting Qualitative Research (COREQ 32) guidelines.<sup>12 13</sup>

Briefly, the RCT is comparing the new PARTNER model of service delivery to usual care.<sup>7</sup> We will recruit 44 general practices and 572 patients with knee OA in urban and regional practices in Victoria and New South Wales, Australia. The patients will be 45 years of age or older, and have had knee pain ( $\geq 4/10$ ) for a minimum of three months. The model has interventions for both the person with OA, and their general practitioner (GP). The GP intervention will provide professional development and training opportunities on the most current conservative, non-surgical management options available for OA, as recommended by national and international clinical guidelines<sup>3-5</sup>. This will include audit/feedback activities, online learning modules, and the Integrated Care (INCA) electronic desktop IT support tool (previously named cdmNET). All GPs in the study regardless of group allocation will be asked to provide an initial evidence-based consultation for their participating patients. If allocated to the intervention arm, patients will be referred to the PARTNER Care Support Team (CST). The CST is a centralised, multidisciplinary team of health professionals trained in best-practice OA management, and with skills in health behaviour change. The CST will support patient participants to manage their knee OA for a period of 12 months. The CST will provide the patients with education, advice and ongoing support for behaviour change on the key OA treatments, including leg strengthening exercises, general physical activity, weight loss, and appropriate use of pain medications as agreed with the patient. Patients with a BMI  $\geq 27$  will have the option of

1  
2  
3 completing the Commonwealth Scientific and Industrial Research Organisation's (CSIRO) online "Total  
4 Wellbeing Diet" (TWD) program<sup>14 15</sup>. The TWD program based on an evidence-based, structured,  
5 nutritionally balanced eating plan designed to be delivered as part of a balanced lifestyle programme.<sup>16</sup>  
6 Patient participants may also be directed to one or more secondary interventions or additional health  
7 care services if they meet the referral criteria and/or have identified it as a personal priority. These  
8 treatment options may include online cognitive behavioural therapy (CBT) programs for mood, pain  
9 coping and sleep, or referrals to health care professionals (e.g. physiotherapists or dieticians) for face-to-  
10 face sessions. The primary outcomes of the PARTNER study are change in self-reported pain and function  
11 at 12-months. We will also assess a range of secondary patient-level outcomes at 6 and 12 months, and  
12 including the cost-effectiveness of the model (see<sup>7</sup>).

13  
14  
15  
16  
17 **Patient and public involvement:** One of the strengths of this process and feasibility evaluation is that it  
18 has been incorporated into the overall study design from conception. Both the main protocol and this  
19 evaluation and feasibility sub-protocol are underpinned by existing theoretical frameworks.<sup>17-21</sup> It has built  
20 upon considerable background work undertaken by our team, and with input from a broad range of  
21 stakeholders, general practitioners and consumers who participated in our five working groups: i)  
22 scientific methods, ii) data, iii) GP model of service delivery, iv) consumer engagement and, v) policy and  
23 marketing. Each working group was chaired by an appropriate representative from either an industry  
24 partner, consumer group, or other stakeholder organisation. This process and feasibility evaluation  
25 protocol has had further input from colleagues with expertise in implementing and assessing health  
26 interventions, and its content has evolved after findings from our pilot work. We send 6 monthly updates  
27 on the study's progress to our stakeholders and participants via an online newsletter.

28  
29  
30  
31 **Theoretical frameworks for the process evaluation:** Figure 1 outlines the PARTNER logic model, which  
32 summarises the key questions, target behaviours, interventions, mediators and outcomes for both GPs  
33 and patients recruited to the study. The development of the model used Wagner's theoretical framework  
34 for the management of chronic disease<sup>17</sup>, the Behaviour Change Wheel and the Theoretical Domains  
35 Framework<sup>18</sup> to identify key intervention components and propose a causal pathway between the study  
36 intervention and the main outcomes.

37  
38  
39  
40  
41 Our methods for the process and feasibility evaluations are based on the recommendations from the UK  
42 Medical Research Council framework for undertaking a process evaluation of complex interventions.<sup>19</sup>  
43 The RE-AIM framework (Reach, Effectiveness, Adoption, Implementation and Maintenance) has further  
44 guided the development of our evaluation questions<sup>20 21</sup>. RE-AIM is recommended by the Osteoarthritis  
45 Research Society International (OARSI) for conducting implementation trials on OA.<sup>9</sup> RE-AIM emphasises  
46 the need to look into the proportion and representativeness of the participants' involved in the trial, the  
47 impact of the intervention, the fidelity and dose of the implementation, and identify issues impacting on  
48 long-term scaling of the model. It covers 5 domains, briefly:

- 49 • *Reach*: did the intervention reach who we intended?
- 50 • *Effectiveness*: was the intervention effective and cost-effective? (this question is primarily  
51 addressed by the RCT)<sup>7</sup>

- *Adoption*: who do we need to target to develop institutional support for the intervention? Did the practices recruited to our study adopt the changes at an organisational level, how representative were these sites compared to other Australian settings, and what needs to be undertaken to have it adopted more widely? Will actual change in the way OA is managed in primary care be achievable with our model, and how well do the end-users (clinicians, patients and other service providers) accept the intervention and processes? <sup>9</sup>
- *Implementation*: was the intervention delivered correctly and consistently (fidelity) as intended at the trial outset?
- *Maintenance*: can the intervention be delivered sustainably in different health care contexts and more broadly?

### Data sources for the PARTNER study

We will use a mixed methods approach that utilises both quantitative and qualitative methods to capture process data for analysis (Table 1, Fig. 1), all of which involve informed consent and have been approved by an ethics committee. Detailed descriptions of the quantitative data collection instruments and analysis have been described previously in the main protocol<sup>7</sup>, with details relevant to this protocol outlined below. The type and timing of data collected to address each aim of the process evaluation, including the details of the qualitative data collection are described in the following sections. Figure 2 illustrates the integration of the process and feasibility evaluations with the main RCT. Briefly, the data collection methods and time points relevant to these evaluations include:

- a. Study administration records: include participant tracking, screening, training, withdrawal and serious adverse event logs; and training logs for the GPs, CST and other trial staff. Data are collected for the duration of the trial.
- b. Electronic survey data from patients and GP surveys. GP complete surveys at baseline and after the study team has confirmed all their patients have attended their first GP consultation. Patients complete surveys at baseline, post GP visit, 3, 6 and 12 months.
- c. Electronic consultation detailed records of each of the CSTs' consultations with the intervention patients over the 12-month period.
- d. Service provider records will be collected from external providers delivering the weight-loss intervention, and the online CBT programs offered to the intervention group (i.e. *painTrainer* and *ThisWayUp*).
- e. Recorded consultation phone calls between the patient and the CST: all patient consultations for the duration of the patient's involvement with the CST will be audio recorded. For the first 18-weeks patients will be contacted once a fortnight on average (9 calls), and then monthly for the next 6 months (6 calls). The actual number and timing of these calls will be agreed between the patient and the CST.
- f. Semi-structured qualitative interviews: these will be undertaken with a selection of GPs, patients and the CST personnel. GP interviews will be undertaken after all their enrolled patients have had their initial GP visit. Patient interviews will be undertaken after they have completed their 12-

1  
2  
3 month survey. The CST interviews will be undertaken after all patients have finished their last  
4 consultation.  
5  
6

### 7 **Quantitative data analysis to address the aims of the process evaluation:**

8

9  
10 We will use a wide selection of the quantitative data to explain the study's effectiveness results in terms  
11 of fidelity and engagement with the intervention, particularly around the consistency of the study's  
12 implementation as per the primary protocol (Fig. 1) and the trial procedures manuals (Aim 1.1). This will  
13 include the study administration records, the electronic survey data collected from both patients and GPs,  
14 the electronic consultation records from the CST, and any changes required to the protocol over the  
15 duration of the study. For the GPs in the intervention group we will also examine how many completed  
16 the required professional development training modules, the optional capacity building training modules,  
17 and the number of intervention patients who were ultimately referred to the CST with OA (i.e. if there  
18 were any patients who were not diagnosed with OA). We will further examine if patients have reported  
19 receiving information on, or discussed with, their GP any of the four key topics (OA education, physical  
20 activity, muscle strengthening and weight-loss), and whether OA management plans were prepared for  
21 each patient. To determine what usual care entailed for our control cohort (Aim 1.2), we will analyse the  
22 electronic survey data from both the GPs and patients, including if there were any unanticipated  
23 treatments prescribed or activities undertaken that may need to be addressed in a future roll out of the  
24 model.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Data collection methods used to address each aim and question of the process evaluation.**

Aims	Data collection method					
	i	ii	iii	iv	v	vi
<b>Aim 1: Explain the trial results in terms of fidelity and engagement:</b>						
1.1 Were the intervention and control arms delivered as intended:						
<i>GPs</i>	X	X			X	X
<i>Patients</i>	X	X	X	X	X	X
<i>CST</i>			X	X		
1.2 What did “usual care” entail?						
<i>GPs</i>		X			X	
<i>Patients</i>		X			X	
1.3 What types of issues were discussed or actioned during the interactions between the CST /GPs and the patients?						
<i>GPs</i>		X			X	
<i>CST</i>		X	X	X	X	
1.4 Participants and healthcare professionals’ perspectives on how, why, and for whom the interactions did or did not work? (semi-structured qualitative interviews)						
<i>GPs</i>					X	
<i>CST</i>					X	
<i>Patients</i>					X	
1.5 Were the primary and secondary outcome effects due to the nature of the implementation or to the intervention?						
<i>GPs</i>		X			X	
<i>Patients</i>		X	X	X	X	
<b>Aim 2: Feasibility of scaling the intervention in Australia</b>						
2.1 What are the possible barriers and enablers to rolling out the model in Australian primary care?						
<i>GPs</i>			X		X	
<i>Patients</i>			X		X	
2.2 Do patients and GPs value the intervention as delivered?						
<i>GPs</i>					X	
<i>Patients</i>					X	
2.3 Are the results generalisable to other patients with OA, healthcare service providers and across states?						
	X				X	
2.4 Is the intervention cost-effective compared to usual care?						

			X		X	X	
--	--	--	---	--	---	---	--

### Table 1: Legend

- i. Analysis of inclusion / exclusion criteria, screening logs and withdrawal logs.
- ii. Analysis of the quantitative data collected in electronic surveys for both the GPs and patients with OA.
- iii. Analysis of a sample of recorded telephone interactions between the CST responsible for providing the intervention and the patients with OA.
- iv. Audit of data collected over the trial (the electronic consultation notes) that captures the number, length and nature of the interactions between the CST and patients with OA.
- v. Semi-structured interviews with patient participants and the GPs and CST involved in the study.
- vi. Audit of training logs and other activity logs for GPs in the interventions group. This includes analysis of web usage statistics.

For the CST we will analyse the study records and survey data to determine the amount of time spent with each patient, and if the key interventions or secondary interventions (mood, pain and sleep management), were discussed in the consultations. Electronic patient survey data, the CST electronic consultation records and a selection of the recorded patient consultations will be further examined to establish what issues or topics were typically discussed during the consultations (Aim 1.3), including any additional issues that may need to be incorporated into the intervention long-term (also see *Qualitative data collection methods* below). We will examine the nature of the support and advice provided to patients by both the GPs and the CST, map the frequency and accuracy of each treatment component to the international care standards for OA (OA Quality Indicators)<sup>22 23</sup>, and identify any conflicting advice that may need to be address when designing future training or educational materials.

We will also use the quantitative data sets to determine the feasibility of having the model adopted broadly in an Australian healthcare context by exploring health care providers' and patients' experience of the intervention and its perceived impact (Aim 2.3). We will undertake an audit of the inclusion and exclusion criteria, and the screening logs for general practices, GPs and patients to identify any reasons for not choosing not to participate and for any loss to follow-up. These data will be compared to the general population to give an indication of the representativeness and generalisability of the results to other patients, healthcare service providers and other Australian states/territories. Collectively, these data will provide some insight into the generalisability of the efficacy results, and any amendments that may need to be incorporated into the current model. This information will also be used to determine the cost effectiveness of the PARTNER model compared to usual care<sup>7</sup>.

### Qualitative data collection:



1  
2  
3 In addition to the quantitative datasets, we will collect and analyse qualitative data that will address many  
4 of the process and feasibility aims of this study (see Table 1). Firstly, we will analyse a sample of the  
5 telephone interactions between the patients in the intervention group and the CST. A selection of 20  
6 purposively selected telephone consultations between the patients and the CST will be chosen after the  
7 final patient is recruited. We aim to ensure maximum heterogeneity of sampling, based on clinical and  
8 demographic characteristics, and gain the perspectives of patients and GPs in both urban and regional /  
9 rural general practices, and smaller versus larger practices. To capture the change in the perspectives over  
10 the 12 months, three phone calls will be analysed per person, covering the initial consultation, one  
11 randomly selected call from the first 18 months of the intervention (intensive phase), and one randomly  
12 selected call from the last 6 months of the CST intervention (maintenance phase). The phone recordings  
13 will be transcribed and analysed using a pre-designed checklist to determine how much time is spent on  
14 the key priority topics and the targeted secondary interventions (mood, pain coping and sleep)(Fig. 1). A  
15 tally will be made of the different types of issues discussed during the calls and the type of information  
16 given (Aim 1.1, 1.3, 1.5). We will also assess if the components of care delivered by the CST are  
17 accompanied by the appropriate behaviour change methods to support self-management as per the  
18 PARTNER protocol. This analysis will be undertaken by a member of the study team involved with the  
19 intervention, and an independent person not involved with running the trial. Data will be compiled and  
20 compared, and if required adjudicated by a third party.

21  
22  
23  
24  
25  
26  
27  
28 Secondly, we will undertake semi-structured qualitative interviews with a selection of patients, GPs and  
29 the CST. These results will also address a range of the aims of these process and feasibility evaluations  
30 (Table 1), and a primary focus on contextual factors affecting delivery and implementation, and thus those  
31 that influence rolling out and long-term sustainability of the PARTNER model (Aims 2.1, 2.2, and 2.3). The  
32 interviews will be conducted over the telephone or face-to-face, by dedicated researcher/s not involved  
33 with delivering the RCT and with experience in qualitative data collection. Our multidisciplinary research  
34 team will develop the semi-structured interviews to explore issues around patients', GPs' and CST  
35 personnel's perspectives on how, why and for whom the interventions did or did not work, positive and  
36 negative (unintentional) outcomes, possible barriers and facilitators to rolling out the intervention,  
37 including any adoption considerations at the setting or organisational (meso) level, if the new model of  
38 care is valued by the users, and if they found any aspects burdensome (i.e. the number of appointments  
39 for patients or the amount of training for GPs).

40  
41  
42  
43  
44  
45 Similar to the selection of recorded CST phone consultations, we will use purposive sampling to gain  
46 perspectives from patients and GPs from different regional and practice-related contexts. This will include  
47 around 30 patients (15 control and 15 intervention) and 14 GPs (7 from each group), or until redundancy  
48 is observed. We will also interview all willing members of the CST. Patients will be different from those  
49 used in the examination of the telephone consultations with the CST and will have finished their  
50 involvement with the trial. The interviews will be conducted one-to-one and will take approximately 1  
51 hour each. Participants will be consented by the interviewer over the phone. The interviews will follow an  
52 interview guide which outlines the broad discussion topics. The draft interview schedule will be tested  
53 with patients and health care professional volunteers prior to use.

1  
2  
3 **Qualitative data analysis plan:** The semi-structured interview data and content data will be thematically  
4 analysed and interpreted. Interviews will be audio-recorded and transcribed verbatim. Transcripts will be  
5 coded and analysed thematically, using methods of constant comparison derived from grounded theory<sup>24</sup>.  
6 Contextual information derived from other process data will be used to triangulate the identified themes.  
7 The logic model (Figure 1) and process evaluation framework (Table 1) will aid the analysis by triangulating  
8 the quantitative data with the relevant qualitative data under each sub-heading. Qualitative data analysis  
9 software 'NVivo' will be used (QSR International, Melbourne, Australia). Identified themes will be  
10 explored, looking for shared or disparate views among the patients, GPs and CST about their experiences  
11 of participation, implementation and operationalisation of the study at their practice (if relevant). The  
12 collection and analysis of the qualitative data will be conducted iteratively so that themes identified in  
13 early interviews can be explored in more depth later.<sup>19</sup>

## 14 15 16 17 18 **ETHICS AND DISSEMINATION**

19  
20  
21 The primary study protocol (2016/959), this sub-study protocol (2019/503), study documents, and all  
22 subsequent amendments have been approved by the Human Research Ethics Committee (HREC) of the  
23 University of Sydney. The study underwent peer review from the Australian National Health and Medical  
24 Research Council (NHMRC) before receiving funding, and the protocol was prospectively registered with  
25 the Australia New Zealand Clinical Trials Registry (ACTRN12617001595303).

26  
27  
28  
29 This protocol outlines the rationale, design and methods for process and feasibility evaluations of the  
30 PARTNER study, a randomised controlled trial designed to test the new PARTNER model of service  
31 delivery. This evaluation of a complex intervention is crucial to explaining the PARTNER study results, and  
32 to determine the feasibility of scaling the intervention in an Australian healthcare context. The data and  
33 results will be used to identify and address issues in the intervention and improve the delivery of the  
34 model long term, with a focus on effectiveness, quality and safety, and scalability.

35  
36  
37  
38 Outcomes from this study, regardless of the effectiveness of the RCT, will directly contribute to the  
39 implementation priorities of the Australian "National Osteoarthritis Strategy"<sup>25</sup>, the aligned jurisdictional  
40 Models of Care in WA<sup>26</sup>, NSW<sup>27</sup> and Victoria<sup>28</sup>, and other associated national strategies<sup>4,29</sup>. The National  
41 OA Strategy has multi-partisan support from peak and professional bodies, governments, private health  
42 insurers and consumers to improve access to evidence-based, non-surgical OA interventions that deliver  
43 high-value care to all Australians with OA. It specifically calls for the prioritisation of testing and  
44 implementation of new models of service delivery to support referral to allied health and community-  
45 based services, assist primary care practitioners to deliver essential lifestyle-based interventions, and  
46 ultimately reduce the over-reliance on medications and joint replacement surgery. Our findings will be  
47 disseminated to all partners and stakeholders involved with both the study's initial design, and those with  
48 an interest in its long-term implementation. The National OA Strategy Leadership Group and  
49 Implementation Advisory Committee will help drive dissemination of our results across all levels of  
50 healthcare to address the local, meso and macro needs identified. At an international level our results will  
51 contribute to the work of the Osteoarthritis Research Society International's "Joint Effort Initiative" who  
52 are currently developing broadscale guidelines and recommendations to assist with the global



1  
2  
3 implementation of OA management programs<sup>30</sup>. Specific research findings will be disseminated via peer-  
4 review journals and conferences, and we anticipate delivering training workshops for interested health  
5 care professionals.  
6  
7

8 In conclusion, this paper reports of the design of the mixed methods process and feasibility evaluations  
9 for the PARTNER study. The results will help us gain a better understanding of the implementation of the  
10 intervention and identify issues for consideration when interpreting its effectiveness. However, these  
11 evaluations will also allow us to identify any broader issues or considerations that will need to be  
12 addressed for a wider rollout of this new model of service delivery in Australian primary care.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

1. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. *Nat Rev Rheumatol* 2014;10(7):437-41. doi: 10.1038/nrrheum.2014.44 [published Online First: 2014/03/26]
2. Meneses SR, Goode AP, Nelson AE, et al. Clinical algorithms to aid osteoarthritis guideline dissemination. *Osteoarthritis Cartilage* 2016;24(9):1487-99. doi: 10.1016/j.joca.2016.04.004 [published Online First: 2016/04/21]
3. National Institute for Health and Care Excellence. Osteoarthritis: Care and management in adults. London: NICE, 2014.
4. Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis (2nd edn). East Melbourne: RACGP, 2018.
5. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 2014;22(3):363-88. doi: 10.1016/j.joca.2014.01.003 [published Online First: 2014/01/28]
6. Runciman WB, Hunt TD, Hannaford NA, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. *Med J Aust* 2012;197(2):100-5. [published Online First: 2012/07/17]
7. Hunter DJ, Hinman RS, Bowden JL, et al. Effectiveness of a new model of primary care management on knee pain and function in patients with knee osteoarthritis: Protocol for THE PARTNER STUDY. *BMC Musculoskelet Disord* 2018;19(1):132. doi: 10.1186/s12891-018-2048-0 [published Online First: 2018/05/02]
8. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655. doi: 10.1136/bmj.a1655 [published Online First: 2008/10/01]
9. Allen KD, Bierma-Zeinstra SM, Foster NE, et al. OARSI Clinical Trials Recommendations: Design and conduct of implementation trials of interventions for osteoarthritis. *Osteoarthritis Cartilage* 2015;23(5):826-38. doi: 10.1016/j.joca.2015.02.772 [published Online First: 2015/05/09]
10. Blyth FM, Briggs AM, Schneider CH, et al. The Global Burden of Musculoskeletal Pain-Where to From Here? *Am J Public Health* 2019;109(1):35-40. doi: 10.2105/AJPH.2018.304747 [published Online First: 2018/11/30]
11. Egerton T, Nelligan R, Setchell J, et al. General practitioners' perspectives on a proposed new model of service delivery for primary care management of knee osteoarthritis: a qualitative study. *BMC Fam Pract* 2017;18(1):85. doi: 10.1186/s12875-017-0656-7 [published Online First: 2017/09/09]
12. Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation Studies (StaRI): explanation and elaboration document. *BMJ Open* 2017;7(4):e013318. doi: 10.1136/bmjopen-2016-013318 [published Online First: 2017/04/05]
13. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;19(6):349-57. doi: 10.1093/intqhc/mzm042 [published Online First: 2007/09/18]
14. Noakes M, Clifton PM. The CSIRO Total Wellbeing Diet. Australia: Penguin Books 2005.
15. Noakes M, Keogh JB, Foster PR, et al. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. *Am J Clin Nutr* 2005;81(6):1298-306. doi: 10.1093/ajcn/81.6.1298 [published Online First: 2005/06/09]
16. Wyld B, Harrison A, Noakes M. The CSIRO Total Wellbeing Diet Book 1: sociodemographic differences and impact on weight loss and well-being in Australia. *Public Health Nutrition* 2010;13(12):2105-10. doi: 10.1017/s136898001000073x [published Online First: 2010/04/16]

17. Wagner EH, Bennett SM, Austin BT, et al. Finding common ground: patient-centeredness and evidence-based chronic illness care. *J Altern Complement Med* 2005;11 Suppl 1:S7-15. doi: 10.1089/acm.2005.11.s-7 [published Online First: 2005/12/08]
18. Michie S, Atkins L, West R. The Behaviour Change Wheel (Behavior Change Wheel) - a guide to designing interventions. 2nd Edition ed. London: Silverback Publishing 2014.
19. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical Research Council guidance. *Bmj* 2015;350:h1258. doi: 10.1136/bmj.h1258 [published Online First: 2015/03/21]
20. Gaglio B, Phillips SM, Heurtin-Roberts S, et al. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research. *Implement Sci* 2014;9:96. doi: 10.1186/s13012-014-0096-x [published Online First: 2014/08/29]
21. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. *Am J Public Health* 1999;89(9):1322-7. [published Online First: 1999/09/04]
22. Blackburn S, Higginbottom A, Taylor R, et al. Patient-reported quality indicators for osteoarthritis: a patient and public generated self-report measure for primary care. *Res Involv Engagem* 2016;2(1):5. doi: 10.1186/s40900-016-0019-x [published Online First: 2016/03/17]
23. Edwards JJ, Jordan KP, Peat G, et al. Quality of care for OA: the effect of a point-of-care consultation recording template. *Rheumatology (Oxford)* 2015;54(5):844-53. doi: 10.1093/rheumatology/keu411 [published Online First: 2014/10/23]
24. Silverman D. Interpreting Qualitative Data. (5th ed.) ed. London, UK: Sage 2014.
25. National Osteoarthritis Strategy Project Group. National Osteoarthritis Strategy: Institute of Bone and Joint Research, University of Sydney, 2018.
26. Department of Health (Western Australia). Service model for community-based musculoskeletal health in Western Australia. Perth: Health Strategy and Networks, Department of Health, Western Australia, 2013.
27. NSW Agency for Clinical Innovation. Osteoarthritis Chronic Care Program Model of Care: ACI, NSW Government; 2018 [Available from: [https://www.aci.health.nsw.gov.au/resources/musculoskeletal/osteoarthritis\\_chronic\\_care\\_program/osteoarthritis-chronic-care-program](https://www.aci.health.nsw.gov.au/resources/musculoskeletal/osteoarthritis_chronic_care_program/osteoarthritis-chronic-care-program) accessed 4/10/2018.
28. Victorian Musculoskeletal Clinical Leadership Group. Victorian Model of Care for Osteoarthritis of the Hip and Knee. Melbourne: MOVE muscle, bone & joint health, 2018.
29. Arthritis Australia. Time to move: Osteoarthritis. Sydney: Arthritis Australia, 2014.
30. Eyles JP, Hunter DJ, Bennell KL, et al. Priorities for the effective implementation of osteoarthritis management programs: an OARSI international consensus exercise. *Osteoarthritis Cartilage* 2019 doi: 10.1016/j.joca.2019.05.015 [published Online First: 2019/06/05]

### **AUTHOR STATEMENT**

KLB, RSH and DJH conceived the initial project and procured the project funding, and DJH is leading the trial. KLB, RSH, DJH and TE developed the primary study protocol, and JLB led the further development of the process evaluation and feasibility protocol. AMB, SJB, ABF, SDF, JK, MP, DJS, and NAZ assisted with both protocol designs. JLB wrote the first and final draft of this manuscript. All authors participated in the trial design, provided feedback on drafts, and read and approved the final manuscript.

### **FUNDING**

This work is supported by a 3-year NHMRC partnership grant (APP1115720) of the Australian Government. The NHMRC has had no role in the design or other components of the study except for funding. The study is co-funded by our Private Health Insurer partner organisations; Medibank Better Health Foundation and Bupa Australia who declare an interest in the outcome. We are receiving further in-kind support, resources and services from Arthritis Australia, Medibank Private, Good2Give, Monash University, Precedence Health Care and HealthChange Australia. The NHMRC Centre of Research Excellence for Translational Research in Musculoskeletal Pain (APP1079078) have provided additional funding and in-kind support for components of the study outside the scope of the NHMRC grant.

### **COMPETING INTERESTS**

DJH provides consulting advice to Pfizer, Lilly, Merck Serono and TLC bio. SB is an employee of Medibank.

## ACKNOWLEDGEMENTS

DJH is supported by a National Health and Medical Research Council Practitioner Fellowship (APP1079777). RSH is supported by a NHMRC Senior Research Fellowship (#1154217). MP has been supported by an NHMRC Career Development Fellowship. KLB is supported by a National Health and Medical Research Council Principal Research Fellowship.


We wish to acknowledge the contribution of all our stakeholders, working groups, partner organisations and their representatives in the design of the PARTNER model and this study, in particular:

- Ms Franca Marine and Ms Ainslie Cahill, Arthritis Australia – educational materials and advice
- Ms Jeanette Gale and Ms Caroline Bills, HealthChange Australia – training for the CST and provision of manuals.
- Professor Michael Georgeff and Dr Marianne Hibbert, Precedence Health Care – INCA software and training
- Dr Kevin Cheng and Ms Rebecca Bell, Medibank Private
- Ms Natalie Dubrowin, Bupa Australia
- The PARTNER CST: Hayley Morey, Joanne Bolton, Kim Allison, Kelly Woosnam, Jane Evans, Liz Dixon, Chris Yeomans and Heidi Williams.
- The PARTNER Study Team: Karen Shuck, Charlotte Marshall, Stephanie Hawkins, Michelle King, Rebecca Doyle, Janet Cook, Carin Pratt, Iqbal Hasan, and Anna Wood.

## FIGURE LEGENDS

**Figure 1: The PARTNER logic model. Theoretical basis for the development of the PARTNER model of service delivery, and the mechanisms underpinning the process evaluation.** GP = General Practitioner; RACGP = Royal Australian College of General Practitioners; INCA = Integrated Care management software (formally cdmNET); COM-B = Capability, Opportunity, Motivation and Behaviour.


**Figure 2: Indicative timing of the data collection processes for GPs and patients.** This schematic illustrates the integration of the process and feasibility evaluations with the main RCT. Open boxes are quantitative data collection, filled boxes are qualitative data (interviews or phone call recordings). The patient intervention is for 12-months. Pt = patients, CST = Care Support Team, GPs = General practitioners, Q = online survey questionnaires. \* data are collected for GPs in the intervention group only.





34526 on 4 February 2020. Downloaded from <http://bmjopen.bmj.com/> by guest on 10 December 2024. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



# BMJ Open

## Protocol for the process and feasibility evaluations of a new model of primary care service delivery for managing pain and function in patients with knee osteoarthritis (PARTNER) using a mixed methods approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034526.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Dec-2019
Complete List of Authors:	Bowden, Jocelyn; The University of Sydney, Institute of Bone and Joint Research; Royal North Shore Hospital, Department of Rheumatology Egerton, T; University of Melbourne, Hinman, Rana S.; University of Melbourne, Bennell, Kim; University of Melbourne, CHESM Briggs, Andrew; Curtin University, School of Physiotherapy and Exercise Science Bunker, Stephen; Medibank Kasza, Jessica; Monash University, School of Public Health and Preventive Medicine French, Simon; Macquarie University, Department of Chiropractic Pirota, Marie; University of Melbourne, General Practice and Primary Care Academic Centre; University of Melbourne, Schofield, Deborah; Macquarie University, Centre for Economic Impacts of Genomic Medicine Zwar, Nicholas; University of New South Wales, School of Public Health and Community Medicine; Bond University, Health Sciences and Medicine Hunter, David; The University of Sydney, Institute of Bone and Joint Research ; Royal North Shore Hospital, Department of Rheumatology
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Evidence based practice, Rheumatology, General practice / Family practice
Keywords:	PRIMARY CARE, model of service delivery, Process Evaluation, Clinical Trial, QUALITATIVE RESEARCH

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title: Protocol for the process and feasibility evaluations of a new model of primary care service delivery for managing pain and function in patients with knee osteoarthritis (PARTNER) using a mixed methods approach**

**Authors:**

Jocelyn L Bowden, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, NSW, Australia. [jocelyn.bowden@sydney.edu.au](mailto:jocelyn.bowden@sydney.edu.au).

Thorlene Egerton, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia. [thorlene.egerton@unimelb.edu.au](mailto:thorlene.egerton@unimelb.edu.au).

Rana S Hinman, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia. [ranash@unimelb.edu.au](mailto:ranash@unimelb.edu.au).

Kim L Bennell, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia. [k.bennell@unimelb.edu.au](mailto:k.bennell@unimelb.edu.au).

Andrew M Briggs, School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia. [a.briggs@curtin.edu.au](mailto:a.briggs@curtin.edu.au).

Stephen J Bunker, Medibank, Docklands, Victoria, Australia; Honorary Senior Fellow, Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia [stephen.bunker@medibank.com.au](mailto:stephen.bunker@medibank.com.au).

Jessica Kasza, Biostatistics Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. [jessica.kasza@monash.edu](mailto:jessica.kasza@monash.edu).

Simon D French, Department of Chiropractic, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia. [simon.french@mq.edu.au](mailto:simon.french@mq.edu.au)

Marie Pirotta, Department of General Practice, The University of Melbourne, Melbourne, Victoria, Australia. [m.pirotta@unimelb.edu.au](mailto:m.pirotta@unimelb.edu.au).

Deborah J Schofield, Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW, 2109, Australia. [deborah.schofield@mq.edu.au](mailto:deborah.schofield@mq.edu.au).

Nicholas A Zwar, School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia; Health Sciences and Medicine, Bond University, Gold Coast, Qld, Australia. [n.zwar@unsw.edu.au](mailto:n.zwar@unsw.edu.au).

1  
2  
3 David J Hunter, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney;  
4 Department of Rheumatology, Royal North Shore Hospital, Sydney, NSW, Australia. [david.hunter@](mailto:david.hunter@sydney.edu.au)  
5 [sydney.edu.au](mailto:david.hunter@sydney.edu.au).  
6  
7  
8  
9  
10

11 **Correspondence to:**

12 Dr Jocelyn Bowden, Institute of Bone and Joint Research, Kolling Institute, The University of Sydney,  
13 Sydney, NSW, Australia. [jocelyn.bowden@sydney.edu.au](mailto:jocelyn.bowden@sydney.edu.au), Ph: +61 2 9463 1898  
14  
15

16 **Key words:** primary care, model of service delivery, process evaluation, clinical trial, qualitative evaluations  
17  
18

19 **Word Count:** 3853 / 4000  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** This protocol outlines the rationale, design and methods for the process and feasibility evaluations of the PARTNER study. PARTNER is a randomised controlled trial to evaluate a new model of service delivery (the PARTNER model) against 'usual care'. PARTNER is designed to encourage greater uptake of key evidence-based non-surgical treatments for knee osteoarthritis (OA) in primary care. The intervention supports general practitioners (GPs) to gain an understanding of the best management options available through online professional development. Their patients receive telephone advice and support for OA management by a centralised, multidisciplinary 'Care Support Team'. We will conduct concurrent process and feasibility evaluations to understand the implementation of this new complex health intervention, identify issues for consideration when interpreting the effectiveness outcomes, and develop recommendations for future implementation, cost effectiveness and scalability.

**Methods and analysis:** The UK Medical Research Council Framework for undertaking a process evaluation of complex interventions and the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) frameworks inform the design of these evaluations. We utilise a mixed methods approach including analysis of survey data, administrative records, consultation records, and semi-structured interviews with general practitioners and their enrolled patients. The analysis will examine fidelity and dose of the intervention, observations of trial setup and implementation, and the quality of the care provided. We will also examine details of "usual care". The semi-structured interviews will be analysed using thematic and content analysis to draw out themes around implementation and acceptability of the model.

**Ethics and dissemination:** The primary and sub-study protocols have been approved by the Human Research Ethics Committee of The University of Sydney (2016/959 and 2019/503). Our findings will be disseminated to national and international partners and stakeholders, who will also assist with wider dissemination of our results across all levels of healthcare. Specific findings will be disseminated via peer-review journals and conferences, and via training for health care professionals delivering osteoarthritis management programs. This evaluation is crucial to explaining the PARTNER study results, and will be used to determine the feasibility of rolling out the intervention in an Australian healthcare context. ACTRN12617001595303, 1/12/2017.

## ARTICLE SUMMARY

### Strengths and limitations of this study

- A comprehensive, pre-planned, process and feasibility evaluation of a complex model of service delivery
- Mixed methods approach, underpinned by theoretical frameworks for design and evaluation of complex health interventions and chronic disease management
- Co-designed by a broad range of stakeholders including general practitioners, people with OA, physiotherapists, rheumatologists, industry groups and policy makers.
- Outcomes from this study will directly contribute to the implementation priorities of the Australian “National Osteoarthritis Strategy”.

## INTRODUCTION

Osteoarthritis (OA) is a leading cause of lower limb pain and disability, affecting more than 2 million Australians.<sup>1</sup> Although there is no cure, there are effective non-surgical treatments for the long-term management of symptomatic OA.<sup>2</sup> In particular, education and advice on OA, exercise and physical activity, and weight management are the core interventions recommended by current clinical guidelines.<sup>3-5</sup> These treatments are, however, often underutilised in primary care, and day-to-day management of Australians with knee OA is inconsistent with these recommendations.<sup>6</sup> We designed the *Effectiveness of a new model of primary care management on knee pain and function in patients with knee osteoarthritis study* (PARTNER), to address this issue.<sup>7</sup> The aim of the PARTNER study is to test a new model of service delivery (the PARTNER model), designed to encourage greater uptake of these key non-surgical treatments in primary care pathways, in comparison to usual care.

The PARTNER model is a complex health intervention (Fig. 1) employing multiple interacting components that target different organisational levels of healthcare delivery.<sup>8</sup> The intervention will target both general practitioners (GPs) and their patients with OA. General practitioners will be provided with online professional development opportunities to gain an understanding of the effective conservative, non-surgical management options available for treatment of patients with OA and endorsed by the Royal Australian College of General Practitioners (RACGP). Their patients will receive tailored advice and support on issues related to the management of OA including physical activity and exercise, weight loss, pain management and other effective self-management behaviours. This support will be delivered remotely for 12-months by a centralised, multidisciplinary 'Care Support Team' (CST) of health professionals trained in best-practice management of OA and health behaviour change.

The effectiveness and cost-effectiveness of this new model is being tested through a two-arm, cluster randomised controlled trial (RCT), and the process and feasibility evaluations described here will be conducted concurrently with the RCT. These evaluations will help us to understand the factors influencing the implementation of the intervention, identify issues for consideration when interpreting the effectiveness results, and enable us to develop recommendations for future implementation of the new model into Australian general practice. This process evaluation and feasibility protocol has two aims, namely:

1. To explain the PARTNER study results in terms of fidelity and engagement with the intervention, and determine:
  - 1.1. whether the intervention and control arms were delivered as intended for both the GPs and patients enrolled in the study,
  - 1.2. what "usual care" entailed, including types and rate of uptake of other services recommended for the patient,
  - 1.3. the types of issues typically identified or actioned during the consultations between the participants and the healthcare professionals in the study (i.e the GPs and CST), and determine the nature of the support and advice provided for each issue,

- 1.4. participants' (GPs and patients) and the CST personnel's perspectives on how, why and for whom the intervention did or did not work, and
  - 1.5. if the primary and secondary outcome effects were due to the nature of the implementation, or to the intervention.<sup>9</sup>
2. To determine the feasibility and acceptability of having the model adopted broadly in an Australian healthcare context (if the study is found to be effective), specifically:
    - 2.1. are there potential barriers and enablers to rolling the model out in the Australian primary care setting that have not been identified previously? We will look at barriers and enablers at the patient level; professional, organisational and service level (meso); and health systems level (macro)<sup>10</sup>
    - 2.2. do people with OA, and GPs, value the intervention as it was delivered?
    - 2.3. are the results generalisable to other people with OA, healthcare service providers and to different Australian health care contexts (e.g. public or private hospitals).
    - 2.4. Is the intervention cost effective compared to usual care?

## METHODS AND ANALYSIS

### The PARTNER Cluster Randomised Controlled Trial:

The PARTNER study is an investigator-initiated pragmatic RCT. A detailed explanation of the background, theoretical development and protocol for the broader PARTNER study (2016/959) has been described previously<sup>7 11</sup>, and the trial prospectively registered with the Australia New Zealand Clinical Trials Registry (ACTRN12617001595303). The process and feasibility evaluations will be reported in accordance with the Standards for Reporting Implementation Studies (STaRI), and the Consolidated Criteria for Reporting Qualitative Research (COREQ 32) guidelines.<sup>12 13</sup>

Briefly, the RCT is comparing the new PARTNER model of service delivery to usual care.<sup>7</sup> We will recruit 44 general practices and 572 patients with knee OA in urban and regional practices in Victoria and New South Wales, Australia. The patients will be 45 years of age or older, and have had knee pain ( $\geq 4/10$ ) for a minimum of three months. The model has interventions for both the person with OA, and their general practitioner (GP). The GP intervention will provide professional development and training opportunities on the most current conservative, non-surgical management options available for OA, as recommended by national and international clinical guidelines<sup>3-5</sup>. This will include audit/feedback activities, online learning modules, and the Integrated Care (INCA) electronic desktop IT support tool (previously named cdmNET). All GPs in the study regardless of group allocation will be asked to provide an initial evidence-based consultation for their participating patients. If allocated to the intervention arm, patients will be referred to the PARTNER Care Support Team (CST). The CST is a centralised, multidisciplinary team of health professionals trained in best-practice OA management, and with skills in health behaviour change. The CST will support patient participants to manage their knee OA for a period of 12 months. The CST will provide the patients with education, advice and ongoing support for behaviour change on the key OA treatments, including leg strengthening exercises, general physical activity, weight loss, and appropriate use of pain medications as agreed with the patient. Patients with a BMI  $\geq 27$  will have the option of



1  
2  
3 completing the Commonwealth Scientific and Industrial Research Organisation's (CSIRO) online "Total  
4 Wellbeing Diet" (TWD) program<sup>14 15</sup>. The TWD program based on an evidence-based, structured,  
5 nutritionally balanced eating plan designed to be delivered as part of a balanced lifestyle programme.<sup>16</sup>  
6 Patient participants may also be directed to one or more secondary interventions or additional health  
7 care services if they meet the referral criteria and/or have identified it as a personal priority. These  
8 treatment options may include online cognitive behavioural therapy (CBT) programs for mood, pain  
9 coping and sleep, or referrals to health care professionals (e.g. physiotherapists or dieticians) for face-to-  
10 face sessions. The primary outcomes of the PARTNER study are change in self-reported pain and function  
11 at 12-months. We will also assess a range of secondary patient-level outcomes at 6 and 12 months, and  
12 including the cost-effectiveness of the model (see<sup>7</sup>).

13  
14  
15  
16  
17 **Patient and public involvement:** One of the strengths of this process and feasibility evaluation is that it  
18 has been incorporated into the overall study design from conception. Both the main protocol and this  
19 evaluation and feasibility sub-protocol are underpinned by existing theoretical frameworks.<sup>17-21</sup> It has built  
20 upon considerable background work undertaken by our team, and with input from a broad range of  
21 stakeholders, general practitioners and consumers who participated in our five working groups: i)  
22 scientific methods, ii) data, iii) GP model of service delivery, iv) consumer engagement and, v) policy and  
23 marketing. Each working group was chaired by an appropriate representative from either an industry  
24 partner, consumer group, or other stakeholder organisation. This process and feasibility evaluation  
25 protocol has had further input from colleagues with expertise in implementing and assessing health  
26 interventions, and its content has evolved after findings from our pilot work. We send 6 monthly updates  
27 on the study's progress to our stakeholders and participants via an online newsletter.

28  
29  
30  
31 **Theoretical frameworks for the process evaluation:** Figure 1 outlines the PARTNER logic model, which  
32 summarises the key questions, target behaviours, interventions, mediators and outcomes for both GPs  
33 and patients recruited to the study. The development of the model used Wagner's theoretical framework  
34 for the management of chronic disease<sup>17</sup>, the Behaviour Change Wheel and the Theoretical Domains  
35 Framework<sup>18</sup> to identify key intervention components and propose a causal pathway between the study  
36 intervention and the main outcomes.

37  
38  
39  
40  
41 Our methods for the process and feasibility evaluations are based on the recommendations from the UK  
42 Medical Research Council framework for undertaking a process evaluation of complex interventions.<sup>19</sup>  
43 The RE-AIM framework (Reach, Effectiveness, Adoption, Implementation and Maintenance) has further  
44 guided the development of our evaluation questions<sup>20 21</sup>. RE-AIM is recommended by the Osteoarthritis  
45 Research Society International (OARSI) for conducting implementation trials on OA.<sup>9</sup> RE-AIM emphasises  
46 the need to look into the proportion and representativeness of the participants' involved in the trial, the  
47 impact of the intervention, the fidelity and dose of the implementation, and identify issues impacting on  
48 long-term scaling of the model. It covers 5 domains, briefly:

- 49 • *Reach*: did the intervention reach who we intended?
- 50 • *Effectiveness*: was the intervention effective and cost-effective? (this question is primarily  
51 addressed by the RCT)<sup>7</sup>



- *Adoption*: who do we need to target to develop institutional support for the intervention? Did the practices recruited to our study adopt the changes at an organisational level, how representative were these sites compared to other Australian settings, and what needs to be undertaken to have it adopted more widely? Will actual change in the way OA is managed in primary care be achievable with our model, and how well do the end-users (clinicians, patients and other service providers) accept the intervention and processes? <sup>9</sup>
- *Implementation*: was the intervention delivered correctly and consistently (fidelity) as intended at the trial outset?
- *Maintenance*: can the intervention be delivered sustainably in different health care contexts and more broadly?

### Data sources for the PARTNER study

We will use a mixed methods approach that utilises both quantitative and qualitative methods to capture process data for analysis (Table 1, Fig. 1), all of which involve informed consent and have been approved by an ethics committee. Detailed descriptions of the quantitative data collection instruments and analysis have been described previously in the main protocol<sup>7</sup>, with details relevant to this protocol outlined below. The type and timing of data collected to address each aim of the process evaluation, including the details of the qualitative data collection are described in the following sections. Figure 2 illustrates the integration of the process and feasibility evaluations with the main RCT. Briefly, the data collection methods and time points relevant to these evaluations include:

- a. Study administration records: include participant tracking, screening, training, withdrawal and serious adverse event logs; and training logs for the GPs, CST and other trial staff. Data are collected for the duration of the trial.
- b. Electronic survey data from patients and GP surveys. GP complete surveys at baseline and after the study team has confirmed all their patients have attended their first GP consultation. Patients complete surveys at baseline, post GP visit, 3, 6 and 12 months.
- c. Electronic consultation detailed records of each of the CSTs' consultations with the intervention patients over the 12-month period.
- d. Service provider records will be collected from external providers delivering the weight-loss intervention, and the online CBT programs offered to the intervention group (i.e. *painTrainer* and *ThisWayUp*).
- e. Recorded consultation phone calls between the patient and the CST: all patient consultations for the duration of the patient's involvement with the CST will be audio recorded. For the first 18-weeks patients will be contacted once a fortnight on average (9 calls), and then monthly for the next 6 months (6 calls). The actual number and timing of these calls will be agreed between the patient and the CST.
- f. Semi-structured qualitative interviews: these will be undertaken with a selection of GPs, patients and the CST personnel. GP interviews will be undertaken after all their enrolled patients have had their initial GP visit. Patient interviews will be undertaken after they have completed their 12-

1  
2  
3 month survey. The CST interviews will be undertaken after all patients have finished their last  
4 consultation.  
5  
6

### 7 **Quantitative data analysis to address the aims of the process evaluation:**

8

9  
10 We will use a wide selection of the quantitative data to explain the study's effectiveness results in terms  
11 of fidelity and engagement with the intervention, particularly around the consistency of the study's  
12 implementation as per the primary protocol (Fig. 1) and the trial procedures manuals (Aim 1.1). This will  
13 include the study administration records, the electronic survey data collected from both patients and GPs,  
14 the electronic consultation records from the CST, and any changes required to the protocol over the  
15 duration of the study. For the GPs in the intervention group we will also examine how many completed  
16 the required professional development training modules, the optional capacity building training modules,  
17 and the number of intervention patients who were ultimately referred to the CST with OA (i.e. if there  
18 were any patients who were not diagnosed with OA). We will further examine if patients have reported  
19 receiving information on, or discussed with, their GP any of the four key topics (OA education, physical  
20 activity, muscle strengthening and weight-loss), and whether OA management plans were prepared for  
21 each patient. To determine what usual care entailed for our control cohort (Aim 1.2), we will analyse the  
22 electronic survey data from both the GPs and patients, including if there were any unanticipated  
23 treatments prescribed or activities undertaken that may need to be addressed in a future roll out of the  
24 model.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Data collection methods used to address each aim and question of the process evaluation.**

Aims	Data collection method					
	i	ii	iii	iv	v	vi
<b><i>Aim 1: Explain the trial results in terms of fidelity and engagement:</i></b>						
1.1 Were the intervention and control arms delivered as intended:						
<i>GPs</i>	X	X			X	X
<i>Patients</i>	X	X	X	X	X	X
<i>CST</i>			X	X		
1.2 What did “usual care” entail?						
<i>GPs</i>		X			X	
<i>Patients</i>		X			X	
1.3 What types of issues were discussed or actioned during the interactions between the CST /GPs and the patients?						
<i>GPs</i>		X			X	
<i>CST</i>		X	X	X	X	
1.4 Participants and healthcare professionals’ perspectives on how, why, and for whom the interactions did or did not work? (semi-structured qualitative interviews)						
<i>GPs</i>					X	
<i>CST</i>					X	
<i>Patients</i>					X	
1.5 Were the primary and secondary outcome effects due to the nature of the implementation or to the intervention?						
<i>GPs</i>		X			X	
<i>Patients</i>		X	X	X	X	
<b><i>Aim 2: Feasibility and acceptability of scaling the intervention in Australia</i></b>						
2.1 What are the possible barriers and enablers to rolling out the model in Australian primary care?						
<i>GPs</i>			X		X	
<i>Patients</i>			X		X	
2.2 Do patients and GPs value the intervention as delivered?					X	
<i>GPs</i>					X	
<i>Patients</i>					X	
2.3 Are the results generalisable to other patients with OA, healthcare service providers and across states?						
	X				X	

2.4 Is the intervention cost-effective compared to usual care?						
<i>Patients</i>		X		X	X	

**Table 1: Legend**

- i. Analysis of inclusion / exclusion criteria, screening logs and withdrawal logs.
- ii. Analysis of the quantitative data collected in electronic surveys for both the GPs and patients with OA.
- iii. Analysis of a sample of recorded telephone interactions between the CST responsible for providing the intervention and the patients with OA.
- iv. Audit of data collected over the trial (the electronic consultation notes) that captures the number, length and nature of the interactions between the CST and patients with OA.
- v. Semi-structured interviews with patient participants and the GPs and CST involved in the study.
- vi. Audit of training logs and other activity logs for GPs in the interventions group. This includes analysis of web usage statistics.

For the CST we will analyse the study records and survey data to determine the amount of time spent with each patient, and if the key interventions or secondary interventions (mood, pain and sleep management), were discussed in the consultations. Electronic patient survey data, the CST electronic consultation records and a selection of the recorded patient consultations will be further examined to establish what issues or topics were typically discussed during the consultations (Aim 1.3), including any additional issues that may need to be incorporated into the intervention long-term (also see *Qualitative data collection methods* below). We will examine the nature of the support and advice provided to patients by both the GPs and the CST, map the frequency and accuracy of each treatment component to the international care standards for OA (OA Quality Indicators)<sup>2223</sup>, and identify any conflicting advice that may need to be addressed when designing future training or educational materials.

We will also use the quantitative data sets to determine the feasibility and acceptability of having the model adopted broadly in an Australian healthcare context. We will explore health care providers' and patients' experience of the intervention and its perceived impact (Aim 2.3) and examine any issues that arose during the trial that would affect broader implementation (Aim 2.1). We will undertake an audit of the inclusion and exclusion criteria, and the screening logs for general practices, GPs and patients to identify any reasons for not choosing not to participate and for any loss to follow-up. These data will be compared to the general population to give an indication of the representativeness and generalisability of the results to other patients, healthcare service providers and other Australian states/territories. Collectively, these data will provide some insight into the generalisability of the efficacy results, and any amendments that may need to be incorporated into the current model. This information will also be used to determine the cost effectiveness of the PARTNER model compared to usual care<sup>7</sup>.

### Qualitative data collection:

In addition to the quantitative datasets, we will collect and analyse qualitative data that will address many of the process and feasibility aims of this study (see Table 1). Firstly, we will analyse a sample of the telephone interactions that have been recorded between the patients in the intervention group and the CST. After the final patient is recruited, we will purposively select 20 patients to conduct a detailed analysis of their telephone consultations. We aim to ensure maximum heterogeneity of sampling, based on clinical and demographic characteristics, and gain the perspectives of patients and GPs in both urban and regional / rural general practices, and smaller versus larger practices. To capture the change in the perspectives over the 12 months, three phone calls will be analysed per person, covering the initial consultation, one randomly selected call from the first 18 months of the intervention (intensive phase), and one randomly selected call from the last 6 months of the CST intervention (maintenance phase). The phone recordings will be transcribed and analysed using pre-designed checklists. The first checklist will be used to determine how much time is spent on the key priority topics and the targeted secondary interventions (mood, pain coping and sleep)(Fig. 1). A tally will be made of the different types of issues discussed during the calls and the type of information given (Aim 1.1, 1.3, 1.5). We will also assess if the components of care delivered by the CST are accompanied by the appropriate behaviour change methods to support self-management as per the PARTNER protocol. We will use a checklist based on the methodology developed by our partner "HealthChange Australia" to train the CST in behaviour change techniques to examine the fidelity of the delivery of the behaviour change component of the intervention. This analysis will be undertaken by a member of the study team involved with the intervention, and an independent person not involved with running the trial. Data will be compiled and compared, and if required adjudicated by a third party.

Secondly, we will undertake semi-structured qualitative interviews with a selection of patients, GPs and the CST. These results will also address a range of the aims of these process and feasibility evaluations (Table 1), and a primary focus on contextual factors affecting delivery and implementation, and thus those that influence rolling out and long-term sustainability of the PARTNER model (Aims 2.1, 2.2, and 2.3). The interviews will be conducted over the telephone or face-to-face, by dedicated researcher/s not involved with delivering the RCT and with experience in qualitative data collection. Our multidisciplinary research team will develop the semi-structured interviews to explore issues around patients', GPs' and CST personnel's perspectives on how, why and for whom the interventions did or did not work, positive and negative (unintentional) outcomes, possible barriers and facilitators to rolling out the intervention, including any adoption considerations at the setting or organisational (meso) level, if the new model of care is valued by the users, and if they found any aspects burdensome (i.e. the number of appointments for patients or the amount of training for GPs).

Similar to the selection of recorded CST phone consultations, we will use purposive sampling to gain perspectives from patients and GPs from different regional and practice-related contexts. This will include around 30 patients (15 control and 15 intervention) and 14 GPs (7 from each group), or until redundancy is observed. We will also interview all willing members of the CST. Patients will be different from those used in the examination of the telephone consultations with the CST and will have finished their

1  
2  
3 involvement with the trial. The interviews will be conducted one-to-one and will take approximately 1  
4 hour each. Participants will be consented by the interviewer over the phone. The interviews will follow an  
5 interview guide which outlines the broad discussion topics. The draft interview schedule will be tested  
6 with patients and health care professional volunteers prior to use.  
7  
8

9  
10 **Qualitative data analysis plan:** The semi-structured interview data and content data will be thematically  
11 analysed and interpreted. Interviews will be audio-recorded and transcribed verbatim. Transcripts will be  
12 coded and analysed thematically, using methods of constant comparison derived from grounded theory<sup>24</sup>.  
13 Contextual information derived from other process data will be used to triangulate the identified themes.  
14 The logic model (Figure 1) and process evaluation framework (Table 1) will aid the analysis by triangulating  
15 the quantitative data with the relevant qualitative data under each sub-heading. Qualitative data analysis  
16 software 'NVivo' will be used (QSR International, Melbourne, Australia). Identified themes will be  
17 explored, looking for shared or disparate views among the patients, GPs and CST about their experiences  
18 of participation, implementation and operationalisation of the study at their practice (if relevant). The  
19 collection and analysis of the qualitative data will be conducted iteratively so that themes identified in  
20 early interviews can be explored in more depth later.<sup>19</sup>  
21  
22  
23

## 24 25 **ETHICS AND DISSEMINATION**

26  
27 The primary study protocol (2016/959), this sub-study protocol (2019/503), study documents, and all  
28 subsequent amendments have been approved by the Human Research Ethics Committee (HREC) of the  
29 University of Sydney. The study underwent peer review from the Australian National Health and Medical  
30 Research Council (NHMRC) before receiving funding, and the protocol was prospectively registered with  
31 the Australia New Zealand Clinical Trials Registry (ACTRN12617001595303).  
32  
33  
34

35 This protocol outlines the rationale, design and methods for process and feasibility evaluations of the  
36 PARTNER study, a randomised controlled trial designed to test the new PARTNER model of service  
37 delivery. This evaluation of a complex intervention is crucial to explaining the PARTNER study results, and  
38 to determine the feasibility of scaling the intervention in an Australian healthcare context. The data and  
39 results will be used to identify and address issues in the intervention and improve the delivery of the  
40 model long term, with a focus on effectiveness, quality and safety, and scalability.  
41  
42  
43

44 Outcomes from this study, regardless of the effectiveness of the RCT, will directly contribute to the  
45 implementation priorities of the Australian "National Osteoarthritis Strategy"<sup>25</sup>, the aligned jurisdictional  
46 Models of Care in WA<sup>26</sup>, NSW<sup>27</sup> and Victoria<sup>28</sup>, and other associated national strategies<sup>4, 29</sup>. The National  
47 OA Strategy has multi-partisan support from peak and professional bodies, governments, private health  
48 insurers and consumers to improve access to evidence-based, non-surgical OA interventions that deliver  
49 high-value care to all Australians with OA. It specifically calls for the prioritisation of testing and  
50 implementation of new models of service delivery to support referral to allied health and community-  
51 based services, assist primary care practitioners to deliver essential lifestyle-based interventions, and  
52 ultimately reduce the over-reliance on medications and joint replacement surgery. Our findings will be  
53 disseminated to all partners and stakeholders involved with both the study's initial design, and those with  
54  
55  
56  
57  
58

1  
2  
3 an interest in its long-term implementation. The National OA Strategy Leadership Group and  
4 Implementation Advisory Committee will help drive dissemination of our results across all levels of  
5 healthcare to address the local, meso and macro needs identified. At an international level our results will  
6 contribute to the work of the Osteoarthritis Research Society International's "Joint Effort Initiative" who  
7 are currently developing broadscale guidelines and recommendations to assist with the global  
8 implementation of OA management programs<sup>30</sup>. Specific research findings will be disseminated via peer-  
9 review journals and conferences, and we anticipate delivering training workshops for interested health  
10 care professionals.  
11  
12  
13

14  
15 In conclusion, this paper reports of the design of the mixed methods process and feasibility evaluations  
16 for the PARTNER study. The results will help us gain a better understanding of the implementation of the  
17 intervention and identify issues for consideration when interpreting its effectiveness. However, these  
18 evaluations will also allow us to identify any broader issues or considerations that will need to be  
19 addressed for a wider rollout of this new model of service delivery in Australian primary care.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. *Nat Rev Rheumatol* 2014;10(7):437-41. doi: 10.1038/nrrheum.2014.44 [published Online First: 2014/03/26]
2. Meneses SR, Goode AP, Nelson AE, et al. Clinical algorithms to aid osteoarthritis guideline dissemination. *Osteoarthritis Cartilage* 2016;24(9):1487-99. doi: 10.1016/j.joca.2016.04.004 [published Online First: 2016/04/21]
3. National Institute for Health and Care Excellence. Osteoarthritis: Care and management in adults. London: NICE, 2014.
4. Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis (2nd edn). East Melbourne: RACGP, 2018.
5. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 2014;22(3):363-88. doi: 10.1016/j.joca.2014.01.003 [published Online First: 2014/01/28]
6. Runciman WB, Hunt TD, Hannaford NA, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. *Med J Aust* 2012;197(2):100-5. [published Online First: 2012/07/17]
7. Hunter DJ, Hinman RS, Bowden JL, et al. Effectiveness of a new model of primary care management on knee pain and function in patients with knee osteoarthritis: Protocol for THE PARTNER STUDY. *BMC Musculoskelet Disord* 2018;19(1):132. doi: 10.1186/s12891-018-2048-0 [published Online First: 2018/05/02]
8. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655. doi: 10.1136/bmj.a1655 [published Online First: 2008/10/01]
9. Allen KD, Bierma-Zeinstra SM, Foster NE, et al. OARSI Clinical Trials Recommendations: Design and conduct of implementation trials of interventions for osteoarthritis. *Osteoarthritis Cartilage* 2015;23(5):826-38. doi: 10.1016/j.joca.2015.02.772 [published Online First: 2015/05/09]
10. Blyth FM, Briggs AM, Schneider CH, et al. The Global Burden of Musculoskeletal Pain-Where to From Here? *Am J Public Health* 2019;109(1):35-40. doi: 10.2105/AJPH.2018.304747 [published Online First: 2018/11/30]
11. Egerton T, Nelligan R, Setchell J, et al. General practitioners' perspectives on a proposed new model of service delivery for primary care management of knee osteoarthritis: a qualitative study. *BMC Fam Pract* 2017;18(1):85. doi: 10.1186/s12875-017-0656-7 [published Online First: 2017/09/09]
12. Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation Studies (StaRI): explanation and elaboration document. *BMJ Open* 2017;7(4):e013318. doi: 10.1136/bmjopen-2016-013318 [published Online First: 2017/04/05]
13. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;19(6):349-57. doi: 10.1093/intqhc/mzm042 [published Online First: 2007/09/18]
14. Noakes M, Clifton PM. The CSIRO Total Wellbeing Diet. Australia: Penguin Books 2005.
15. Noakes M, Keogh JB, Foster PR, et al. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. *Am J Clin Nutr* 2005;81(6):1298-306. doi: 10.1093/ajcn/81.6.1298 [published Online First: 2005/06/09]
16. Wyld B, Harrison A, Noakes M. The CSIRO Total Wellbeing Diet Book 1: sociodemographic differences and impact on weight loss and well-being in Australia. *Public Health Nutrition* 2010;13(12):2105-10. doi: 10.1017/s136898001000073x [published Online First: 2010/04/16]

17. Wagner EH, Bennett SM, Austin BT, et al. Finding common ground: patient-centeredness and evidence-based chronic illness care. *J Altern Complement Med* 2005;11 Suppl 1:S7-15. doi: 10.1089/acm.2005.11.s-7 [published Online First: 2005/12/08]
18. Michie S, Atkins L, West R. The Behaviour Change Wheel (Behavior Change Wheel) - a guide to designing interventions. 2nd Edition ed. London: Silverback Publishing 2014.
19. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical Research Council guidance. *Bmj* 2015;350:h1258. doi: 10.1136/bmj.h1258 [published Online First: 2015/03/21]
20. Gaglio B, Phillips SM, Heurtin-Roberts S, et al. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research. *Implement Sci* 2014;9:96. doi: 10.1186/s13012-014-0096-x [published Online First: 2014/08/29]
21. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. *Am J Public Health* 1999;89(9):1322-7. [published Online First: 1999/09/04]
22. Blackburn S, Higginbottom A, Taylor R, et al. Patient-reported quality indicators for osteoarthritis: a patient and public generated self-report measure for primary care. *Res Involv Engagem* 2016;2(1):5. doi: 10.1186/s40900-016-0019-x [published Online First: 2016/03/17]
23. Edwards JJ, Jordan KP, Peat G, et al. Quality of care for OA: the effect of a point-of-care consultation recording template. *Rheumatology (Oxford)* 2015;54(5):844-53. doi: 10.1093/rheumatology/keu411 [published Online First: 2014/10/23]
24. Silverman D. Interpreting Qualitative Data. (5th ed.) ed. London, UK: Sage 2014.
25. National Osteoarthritis Strategy Project Group. National Osteoarthritis Strategy: Institute of Bone and Joint Research, University of Sydney, 2018.
26. Department of Health (Western Australia). Service model for community-based musculoskeletal health in Western Australia. Perth: Health Strategy and Networks, Department of Health, Western Australia, 2013.
27. NSW Agency for Clinical Innovation. Osteoarthritis Chronic Care Program Model of Care: ACI, NSW Government; 2018 [Available from: [https://www.aci.health.nsw.gov.au/resources/musculoskeletal/osteoarthritis\\_chronic\\_care\\_program/osteoarthritis-chronic-care-program](https://www.aci.health.nsw.gov.au/resources/musculoskeletal/osteoarthritis_chronic_care_program/osteoarthritis-chronic-care-program) accessed 4/10/2018.
28. Victorian Musculoskeletal Clinical Leadership Group. Victorian Model of Care for Osteoarthritis of the Hip and Knee. Melbourne: MOVE muscle, bone & joint health, 2018.
29. Arthritis Australia. Time to move: Osteoarthritis. Sydney: Arthritis Australia, 2014.
30. Eyles JP, Hunter DJ, Bennell KL, et al. Priorities for the effective implementation of osteoarthritis management programs: an OARSI international consensus exercise. *Osteoarthritis Cartilage* 2019 doi: 10.1016/j.joca.2019.05.015 [published Online First: 2019/06/05]

### **AUTHOR STATEMENT**

KLB, RSH and DJH conceived the initial project and procured the project funding, and DJH is leading the trial. KLB, RSH, DJH and TE developed the primary study protocol, and JLB led the further development of the process evaluation and feasibility protocol. AMB, SJB, ABF, SDF, JK, MP, DJS, and NAZ assisted with both protocol designs. JLB wrote the first and final draft of this manuscript. All authors participated in the trial design, provided feedback on drafts, and read and approved the final manuscript.

### **FUNDING**

This work is supported by a 3-year NHMRC partnership grant (APP1115720) of the Australian Government. The NHMRC has had no role in the design or other components of the study except for funding. The study is co-funded by our Private Health Insurer partner organisations; Medibank Better Health Foundation and Bupa Australia who declare an interest in the outcome. We are receiving further in-kind support, resources and services from Arthritis Australia, Medibank Private, Good2Give, Monash University, Precedence Health Care and HealthChange Australia. The NHMRC Centre of Research Excellence for Translational Research in Musculoskeletal Pain (APP1079078) have provided additional funding and in-kind support for components of the study outside the scope of the NHMRC grant.

### **COMPETING INTERESTS**

DJH provides consulting advice to Pfizer, Lilly, Merck Serono and TLC bio. SB is an employee of Medibank.

## ACKNOWLEDGEMENTS

DJH is supported by a National Health and Medical Research Council Practitioner Fellowship (APP1079777). RSH is supported by a NHMRC Senior Research Fellowship (#1154217). MP has been supported by an NHMRC Career Development Fellowship. KLB is supported by a National Health and Medical Research Council Principal Research Fellowship.


We wish to acknowledge the contribution of all our stakeholders, working groups, partner organisations and their representatives in the design of the PARTNER model and this study, in particular:

- Ms Franca Marine and Ms Ainslie Cahill, Arthritis Australia – educational materials and advice
- Ms Jeanette Gale and Ms Caroline Bills, HealthChange Australia – training for the CST and provision of manuals.
- Professor Michael Georgeff and Dr Marianne Hibbert, Precedence Health Care – INCA software and training
- Dr Kevin Cheng and Ms Rebecca Bell, Medibank Private
- Ms Natalie Dubrowin, Bupa Australia
- The PARTNER CST: Hayley Morey, Joanne Bolton, Kim Allison, Kelly Woosnam, Jane Evans, Liz Dixon, Chris Yeomans and Heidi Williams.
- The PARTNER Study Team: Karen Shuck, Charlotte Marshall, Stephanie Hawkins, Michelle King, Rebecca Doyle, Janet Cook, Carin Pratt, Iqbal Hasan, and Anna Wood.

## FIGURE LEGENDS

**Figure 1: The PARTNER logic model. Theoretical basis for the development of the PARTNER model of service delivery, and the mechanisms underpinning the process evaluation.** GP = General Practitioner; RACGP = Royal Australian College of General Practitioners; INCA = Integrated Care management software (formally cdmNET); COM-B = Capability, Opportunity, Motivation and Behaviour.

**Figure 2: Indicative timing of the data collection processes for GPs and patients.** This schematic illustrates the integration of the process and feasibility evaluations with the main RCT. Open boxes are quantitative data collection, filled boxes are qualitative data (interviews or phone call recordings). The patient intervention is for 12-months. Pt = patients, CST = Care Support Team, GPs = General practitioners, Q = online survey questionnaires. \* data are collected for GPs in the intervention group only.



34526 on 4 February 2020. Downloaded from <http://bmjopen.bmj.com/> by guest on 10 December 2024. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

